کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
8738572 | 1591730 | 2018 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial
ترجمه فارسی عنوان
دوز بالای آمیکاسین در مقایسه با استاندارد در بیماران اورژانس بیمارستان با سپسیس شدید و شوک سپتیک: یک کارآزمایی کنترل شده تصادفی
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
آمینوگلیکوزید، فارماکوکینتیک، فارماکودینامیک، سپسیس، شوک سپتیک، بخش اورژانس،
موضوعات مرتبط
علوم زیستی و بیوفناوری
ایمنی شناسی و میکروب شناسی
میکروبیولوژی و بیوتکنولوژی کاربردی
چکیده انگلیسی
Recent studies suggest that intensive care unit patients treated with amikacin frequently do not attain the desired pharmacokinetic/pharmacodynamic (PK/PD) target, i.e. peak amikacin concentration (Cpeak) to minimum inhibitory concentration (MIC) ratio of â¥8, when a single dose of 15âmg/kg is used. No data are available for patients admitted to the emergency department (ED). The aim of this prospective randomised controlled study was to determine PK/PD target attainment in ED patients presenting with severe sepsis or septic shock treated with 15âmg/kg versus 25âmg/kg amikacin. Patients were randomly assigned to receive amikacin 25âmg/kg or 15âmg/kg. Amikacin Cpeak values were determined. The primary outcome was target attainment defined as Cpeak/MICââ¥â8 both using EUCAST susceptibility breakpoints and actually documented MICs as denominator. A total of 104 patients were included. The EUCAST-based target was attained in 76% vs. 40% of patients assigned to the 25âmg/kg vs. 15âmg/kg dose groups (Pâ<0.0001). Target attainment using actual MICs (median of 2âmg/L, documented in 48 isolated Gram-negative pathogens) was achieved in 95% vs. 94% of patients in the 25âmg/kg vs. 15âmg/kg dose groups (Pâ=â0.969). Risk factors associated with PK/PD target failure were identified in the multivariable analysis. At least 25âmg/kg amikacin as a single dose should be used in ED patients with severe sepsis and septic shock to attain the EUCAST-based PK/PD target. However, when using local epidemiology as denominator, 15âmg/kg appears to be sufficient. [ClinicalTrials.gov ID: NCT02365272.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: International Journal of Antimicrobial Agents - Volume 51, Issue 4, April 2018, Pages 562-570
Journal: International Journal of Antimicrobial Agents - Volume 51, Issue 4, April 2018, Pages 562-570
نویسندگان
Sabrina De Winter, Joost Wauters, Wouter Meersseman, Jan Verhaegen, Eric Van Wijngaerden, Willy Peetermans, Pieter Annaert, Sandra Verelst, Isabel Spriet,